Cisplatin is a chemotherapeutic drug broadly used in the treatment of solid tumors. However, patients under this chemotherapy develop severe adverse effects, being nephrotoxicity the most frequent. Cisplatin-induced nephrotoxicity has been associated with oxidative stress, inflammation and apoptosis. Morin, a rather abundant flavonoid, presents antioxidant properties and, at the same time, decreases viability in some tumor cells. Taking into account these facts, it has been hypothesized that morin could attenuate cisplatin-induced kidney injury without interfering with antineoplastic activity of cisplatin. The aim of this study was to evaluate the potential cytoprotective effect of morin against cisplatin-induced damage in the Lilly Laboratories cell-porcine kidney 1 (LLC-PK1) cell line. In addition, the effect of pretreatment with morin on the toxicity of cisplatin on human urinary bladder transitional cell carcinoma T24 cell line was investigated. It was found that 200 μM morin attenuates cisplatin-induced damage on LLC-PK1 cells in a heme oxygenase-1 (HO-1) dependent-way. Moreover, it was found that 200 μM morin alone, decreases T24 cell viability in the same proportion as cisplatin. However, when T24 cells were pretreated with morin, the cell viability did not change compared to the cells treated only with cisplatin.
(a) DwivediC., Abu-GhazalehA., GuentherJ. (1996) Effects of diallyl sulfide and diallyl disulfide on cisplatin-induced changes in glutathione and glutathione-S-transferase activity. Anticancer Drugs, 7, 792–794; (b) Bhuvarahamurthy V, Balasubramanian N, Govindasamy S. (1996) Effect of radiotherapy and chemotherapy on circulating antioxidant system of human uterine cervical carcinoma. Molecular and Cellular Biochemistry, 158, 17–23; (c) Karbownik A, Edyta S, Urjasz H, Głęboka A, Mierzwa E, Grześkowiak E. (2012) The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%. Contemporary Oncology, 16, 435–439.
2.
(a) HartmannJ.T., FelsL.M., KnopS., StoltH., KanzL., BokemeyerC. (2000) A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. Investigational New Drugs, 18, 281–289; (b) Dasari S, Tchounwou PB. (2014) Cisplatin in cancer therapy: molecular mechanisms of action. European Journal of Pharmacology, 5, 364–378; (c) Sastry J, Kellie SJ. (2005) Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatric Hematology and Oncology, 22, 441–445.
3.
(a) MillerR.P., TadagavadiR.K., RameshG., ReevesW.B. (2010) Mechanisms of Cisplatin Nephrotoxicity. Toxins, 2, 2490–2518; (b) Cornelison TL, Reed E. (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecologic oncology, 50, 147–58; (c) Jin F, Terwilliger T, Bosch J, O'Donnell RW. (2013) Effects of sulforaphane on three tumor cell lines and one normal cell line. The FASEB Journal, 27, Supplement 1028.6; (d) Song KI, Park JY, Lee S, Lee D, Jang HJ, Kim SN, Ko H, Kim HY, Lee JW, Hwang GS, Kang KS, Yamabe N. (2015) Protective effect of tetrahydrocurcumin against cisplatin-induced renal damage: in vitro and in vivo Studies. Planta Medica, 81, 286–291.
4.
(a) RicardoK.F.S., Toledo de OliveiraT., NagemT.J., PintoA.S., OliveiraM.G.A. (2001) Effect of flavonoids morin; quercetin and nicotinic acid on lipid metabolism of rats experimentally fed with Triton. Brazilian Archives of Biology and Technology, 44, 263–267; (b) Heeba GH, Mahmoud ME. (2014) Therapeutic potential of morin against liver fibrosis in rats: Modulation of oxidative stress, cytokine production and nuclear factor kappa B. Environmental Toxicology and Pharmacology, 37, 662–671; (c) Sinha K, Sadhukhan P, Saha S, Pal PB, Sil PC. (2015) Morin protects gastric mucosa from nonsteroidal anti-inflammatory drug, indomethacin induced inflammatory damage and apoptosis by modulating NF-κB pathway. Biochimica et Biophysica Acta, 1850, 769–783; (d) Park JY, Kang KA, Kim KC, Cha JW, Kim EH, Hyun JW. (2013) Morin induces heme oxygenase-1 via ERK-Nrf2 signaling pathway. Journal of Cancer Prevention, 18, 249–256.
5.
(a) AthiraK.V., MadhanaR.M., KasalaE.R., SamudralaP.K., LahkarM., GogoiR. (2016) Morin hydrate mitigates cisplatin-induced renal and hepatic injury by impeding oxidative/nitrosative stress and inflammation in mice. Journal of Biochemical and Molecular Toxicology, 30, 571–579; (b) Wei Z, He X, Kou J, Wang J, Chen L, Yao M, Zhou E, Fu Y, Guo C, Yang Z. (2015) Renoprotective mechanisms of morin in cisplatin-induced kidney injury. International Immunopharmacology, 28, 500–506; (c) Kaltalioglu K, Coskun-Cevher S. (2016) Potential of morin and hesperidin in the prevention of cisplatin-induced nephrotoxicity. Renal Failure, 38, 1291–1299.
6.
(a) MegyesiJ., SafirsteinR.L., PriceP.M. (1998) Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. Journal of Clinical Investigation, 101, 777–782; (b) Li S, Basnakian A, Bhatt R, Megyesi J, Gokden N, Shah SV, Portilla D. (2004) PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. American Journal of Physiology-Renal physiology, 287, 990–998; (c) Tsuruya K, Ninomiya T, Tokumoto M, Hirakawa M, Masutani K, Taniguchi M, Fukuda K, Kanai H, Kishihara K, Hirakata H, Iida M. (2003) Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death. Kidney International, 63, 72–82
7.
(a) KimT., KimY.J., HanI.H., LeeD., HamJ., KangK.S., LeeJ.W. (2015) The synthesis of sulforaphane analogues and their protection effect against cisplatin induced cytotoxicity in kidney cells. Bioorganic & Medicinal Chemistry Letters, 25, 62–66; (b) Bunel V, Antoine MH, Nortier J, Duez P, Stévigny C. (2014) Protective effects of schizandrin and schizandrin B towards cisplatin nephrotoxicity in vitro. Journal of Applied Toxicology, 34, 1311–1319; (c) Shiraishi F, Curtis LM, Truong L, Poss K, Visner GA, Madsen K, Nick HS, Agarwal A. (2000) Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. American Journal of Physiology-Renal Physiology, 278, 726–736.
8.
(a) SchaafG.J., MaasR.F., de GroeneE.M., Fink-GremmelsJ. (2002) Management of oxidative stress by heme oxygenase-1 in cisplatin-induced toxicity in renal tubular cells. Free Radical Research, 36, 835–843; (b) Kuo HM, Chang LS, Lin YL, Lu HF, Yang JS, Lee JH, Chung JG. (2007) Morin Inhibits the Growth of Human Leukemia HL-60 Cells via Cell Cycle Arrest and Induction of Apoptosis through Mitochondria Dependent Pathway. Anticancer Research, 27, 395–406; (c) Brown J, O'Prey J, Harrison PR. (2003) Enhanced sensitivity of human oral tumours to the flavonol, morin, during cancer progression: involvement of the Akt and stress kinase pathways. Carcinogenesis, 24, 171–177.
